Rakovina Therapeutics Inc.
RKV.V
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 358.32% | 161.25% | 61.90% | 40.43% | 18.75% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 187.30% | 104.94% | 57.81% | 26.87% | 7.25% |
| Operating Income | -187.30% | -104.94% | -57.81% | -26.87% | -7.25% |
| Income Before Tax | -172.16% | -99.53% | -54.41% | -33.95% | -17.62% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -172.16% | -99.53% | -54.41% | -33.95% | -17.62% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -172.16% | -99.53% | -54.41% | -33.95% | -17.62% |
| EBIT | -187.30% | -104.94% | -57.81% | -26.87% | -7.25% |
| EBITDA | -233.97% | -132.59% | -75.48% | -35.36% | -8.78% |
| EPS Basic | -35.00% | -39.47% | -20.29% | -32.81% | -17.65% |
| Normalized Basic EPS | -34.00% | -35.42% | -20.93% | -32.50% | -19.05% |
| EPS Diluted | -73.75% | -71.05% | -10.67% | -14.86% | -8.11% |
| Normalized Diluted EPS | -34.00% | -35.42% | -20.93% | -32.50% | -19.05% |
| Average Basic Shares Outstanding | 100.86% | 43.36% | 28.45% | 1.29% | 0.37% |
| Average Diluted Shares Outstanding | 100.86% | 43.36% | 28.45% | 1.29% | 0.37% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |